Heartsciences inc HSCS.US 總覽分析

美股醫療保健
(HSCS 無簡報檔)

HSCS 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

公司發布財報數據季度不足,尚無法提供評分

HSCS 近期報酬表現

-4.04%

Heartsciences inc

2.24%

同產業平均

0.72%

S&P500

與 HSCS 同產業的標的表現

  • RSLS Reshape lifesciences inc
    價值 3 分趨勢 2 分波段 5 分籌碼 1 分股利 1 分
    查看更多

HSCS 公司資訊

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

HSCS 股價